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Introduction: Phosphatase and tensin homolog (PTEN) has been 
established as a tumor suppressor gene with an important role in 
regulating the phosphatidylinositol-3-kinase/AKT antiapoptotic and 
survival pathway. The prognostic role of PTEN in non–small-cell 
lung carcinoma has not been evaluated completely in the context of 
other molecular information.
Methods: Tissue microarrays containing 152 resected non–small-cell 
lung cancer specimens were used to investigate PTEN and p53 by immu-
nohistochemistry and PTEN by fluorescence in situ hybridization. DNA 
was isolated and subjected to mutational profiling using the Sequenom 
Oncocarta v1.0 panel. Clinicopathological features were correlated with 
PTEN expression, gene copy number, and mutation status.
Results: PTEN staining was absent in 63 (41.4%) of the cases. 
Significantly more squamous cell carcinomas compared with adeno-
carcinomas demonstrated loss of (negative) PTEN staining (26 of 44 
[59%] versus 32 of 94 [34%]; p = 0.009). PTEN gene copy deletion 
was present in only seven of 124 evaluable cases (5.6%); all deleted 
cases were immunohistochemistry negative. In univariate and mul-
tivariate (MV) analyses adjusted for sex, age, histology, and stage, 
loss of PTEN protein expression was associated with significantly 
shorter disease-free survival (MV hazard ratio: 1.78, 95% confidence 
interval: 1.01–3.14, p = 0.048), whereas no significant associations 
were seen with p53 or KRAS and epidermal growth factor receptor 
(EGFR) mutation status. Importantly, the prognostic value of absent 
PTEN staining was limited to adenocarcinomas, with MV disease-
free survival hazard ratio of 2.68 (95% confidence interval: 1.35–
5.32, p = 0.005), whereas no such association was seen in squamous 
cell carcinomas.
Conclusion: Absence of PTEN protein expression is an independent 
prognostic marker in early-stage resected lung adenocarcinoma.
Key Words: Phosphatase and tensin homolog, Non–small cell lung 
carcinoma, Adenocarcinoma, Prognosis.
(J Thorac Oncol. 2012;7: 1513–1521)
Lung cancer is one of the leading causes of cancer death in Western countries.1 Non–small-cell lung carcinoma 
(NSCLC) accounts for 70% to 80% of all lung cancers, and 
comprises several distinct histologic subtypes, the most com-
mon being squamous cell carcinoma (SqCC), adenocarci-
noma (AdC), and large cell carcinoma. As our understanding 
of the genetic alterations associated with the development 
and progression of NSCLC grows, it is now evident that even 
within a clearly identifiable histologic subtype such as adeno-
carcinoma, distinct molecular changes may be associated with 
a spectrum of clinical characteristics that also correlate with 
disease outcome and response to treatment.2
The phosphatase and tensin homolog (PTEN) gene on 
chromosome 10 was cloned in 1997 through its association with 
the human cancer susceptibility locus at 10q23.3–6 The PTEN 
protein functions as a lipid phosphatase, dephosphorylating 
phosphatidylinositol (3,4,5)-triphosphate, thereby negatively 
regulating the phosphatidylinositol 3-kinase/AKT (PI3K/AKT) 
antiapoptotic and proliferation pathway.7–10 PTEN is reported 
to play a role in apoptosis, cell cycle arrest, cell migration, and 
metastasis.10–15 Loss of PTEN protein expression has been linked to 
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shorter survival times in patients with NSCLC, tongue cancer, and 
with more advanced or poorly differentiated tumor in esophageal 
and oral squamous cell cancers, respectively.16–18 In addition, 
PTEN is a key downstream component of the epidermal growth 
factor receptor (EGFR) pathway.19 Inhibition of this pathway with 
EGFR tyrosine kinase inhibitors (TKIs) has been a successful 
treatment strategy for patients with advanced NSCLC, particularly 
those whose tumors harbor activating EGFR mutations in exons 
19 and 21.20,21 Recent reports suggest that alterations of PTEN also 
are associated with EGFR TKI resistance.22,23 Therefore, further 
insights into the role of PTEN in NSCLC may provide important 
prognostic and predictive information especially in tumors that 
develop resistance to EGFR TKIs.
In this study we conducted a comprehensive analysis to 
correlate PTEN protein expression with gene copy number, 
p53 expression, and mutations in the EGFR and KRAS genes 
in surgically resected NSCLCs. We also investigated the rela-
tionship between PTEN status, clinicopathological character-
istics, and survival outcomes in these patients.
MATERIALS AND METHODS
Tissue Samples
The study was conducted with an approved protocol from 
the Research Ethics Board of the University Health Network. 
Tissue microarrays (TMAs) were constructed using forma-
lin-fixed paraffin embedded archival blocks of patients who 
underwent surgical resection of their NSCLC at the University 
Health Network, using the manual tissue arrayer (Beecher 
Instruments, Silver Spring, MD). Guided by hematoxylin and 
eosin (H&E)-stained slides, 0.6-mm cores were taken from 
three areas of high-tumor cellularity, and one from non-neo-
plastic lung tissue. These cores were arrayed into TMA blocks 
and DNA was isolated from additional tumor cell rich areas of 
the same blocks by further coring. Tumor staging was based on 
the 7th edition of the tumor, lymph node, and the metastasis 
classification from the International Union Against Cancer.24 
The histological classification was based on the 2004 World 
Health Organization classification of lung neoplasms.25 None 
of these patients received EGFR TKIs before surgical resection.
PTEN Immunohistochemistry Analysis
The PTEN antibody (138G6, Cell Signaling Technology, 
Danvers, MA) was used and immunohistochemistry (IHC) 
analysis was carried out on the Ventana Benchmark XT auto-
stainer using the iVIEW DAB detection system for PTEN. 
Sangale et al.26 previously confirmed the specificity of this 
antibody using cell lines with known PTEN genotype. We also 
independently confirmed the specificity in our own laboratory 
by Western blotting (data not shown). Importantly, the PTEN 
immunostaining has a built-in control on each section as the 
tumor stromal fibroblasts and endothelial cells show strongly 
positive (2+) staining (Fig. 1). Loss of expression is represented 
by an absence of staining of tumor cell cytoplasm (Fig. 1A, 
B versus D). Weaker staining that can be distinguished 
from the background staining level of stromal cells was 
FIGURE 1. Representative images 
of PTEN immunohistochemistry. 
A, Low magnification and (B) high 
magnification, tumor showing 
complete lack of staining for PTEN. 
C, Low magnification and (D) high 
magnification, tumor showing 
positive staining for PTEN. PTEN, 
phosphatase and tensin homolog.
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still considered partially positive (1+) for PTEN expression 
(Fig. 1C). Loss of PTEN expression was defined as complete 
absence of cytoplasmic staining in tumor cells. Two patholo-
gists (NY and MAS) evaluated the results independently and 
discrepant cases were evaluated together with a third patholo-
gist (MST), to reach a final consensus decision.
PTEN FISH Analysis
The fluorescence in situ hybridization (FISH) probes 
include the Vysis chromosome 10 centromeric probe labeled 
with Spectrum Aqua (Abbott Laboratories, Abbott Park, IL) 
and a PTEN probe represented by the bacterial artificial chro-
mosome RP11- 846G17 located at 10q23.31 (purchased from 
the Center for Applied Genomics Toronto, Canada, labeled 
with Spectrum Green).
Probe hybridization was performed using standard FISH 
techniques. Briefly, 5-micron TMA slides were incubated at 
56ºC for 24 hours, deparaffinized with xylene, and dehydrated 
in 100% ethanol. For antigen retrieval, the TMA sections were 
placed in 10 mM sodium citrate (SSC), pH 6.4, at 80ºC for 50 
minutes and rinsed sequentially in SSC and dH
2
O. The slides 
were then digested with 750 U/ml pepsin in 0.01 N HCl solu-
tion at 37ºC for 18 minutes, then in dH
2
O, pH 7.0, at room 
temperature for 10 minutes and dehydration in an ascending 
ethanol series for 2 minutes each. Each probe was then added 
to the hybridization areas, cover slipped, and sealed with 
rubber cement. Codenaturation was carried out at 80ºC for 
10 minutes in a microprocessor-controlled system (Hybrite; 
Abbott Laboratories), and the sections were hybridized at 
37ºC overnight. Two posthybridization washes consisted of 
SSC, pH 7.0, containing 0.3% octylphenyl-polyethylene gly-
col (IGEPAL) for 2 minutes at 72ºC followed by 2 minutes in 
SSC, pH 7.0, at room temperature. After rinsing in dH
2
O, the 
slides were air dried in a dark chamber; this was followed by 
nuclear counterstaining with 4´,6-diamidino-2-phenylindole 
(Vector Laboratories, Burlingame, CA).
PTEN copy number was evaluated by dual-color FISH 
in 100 tumor nuclei with an inhouse PTEN probe labeled 
with Spectrum Green and a Vysis Chromosome Enumerating 
Probe for chromosome 10 (Abbott Laboratories, Abbott Park, 
IL) labeled with Spectrum Aqua. As nuclei of NSCLC are 
known to vary in size with ploidy, a relatively high cutoff of 
63% was used to address loss of signal secondary to nuclear 
truncation.27,28 This cutoff is equivalent to 2 SD above the 
mean percent cells with one signal of the PTEN probe and 
two signals of the control chromosome enumerating probe in 
appropriate control nuclei.
KRAS and EGFR Mutational Profiling 
and P53 Immmunohistochemistry
KRAS and EGFR mutations were analyzed by mass spec-
trometric profiling for mutational sequence variants using the 
OncoCarta Panel v1.0 (Sequenom, San Diego, CA), as reported 
previously.29 Standard Sanger sequencing methodology veri-
fied all identified mutations. p53 Immunohistochemistry 
was performed using the DO-7 mouse monoclonal antibody 
(Vector Laboratories, Burlington, Ontario, Canada) using a 
Ventana Benchmark XT autostainer.
Statistical Analysis
Demographic proportions in alteration of PTEN were 
compared using Fisher’s exact test of association for sex, 
histology, smoking history, p53 immunostaining, as well 
as EGFR and KRAS mutation status. The Mann-Whitney 
test was used to test for differences in age, whereas the 
Cochran–Armitage test was used to test for trend in stage. 
Disease-free survival (DFS) was defined as the time from 
surgery until date of relapse, death, or the last recorded date 
of follow-up. The Kaplan–Meier method was used to cal-
culate 3-year DFS probabilities, and survival curves were 
compared with a log-rank test. Variables of interest were 
tested in the presence of other clinical factors using a Cox 
proportional hazards model. A two sided p value of 0.05 
was considered statistically significant. All statistical analy-
ses were performed using the open-source statistical soft-
ware R, version 2.12.1.
RESULTS
Tumors from 152 patients who underwent curative sur-
gical resection for primary NSCLC at the University Health 
TABLE 1. Clinicopathological Characteristics of Patients 
Studied
Characteristics Total Patients = 152
Age
 Median (yrs) (range) 66.9 (42–88)
Sex
 Female 77 (50.7%)
 Male 75 (49.3%)
Histology
 Adenocarcinoma 94 (61.8%)
 Squamous cell carcinoma 44 (28.9%)
 Others 14 (9.2%)
TNM stage
 I 89 (58.6%)
 II 29 (19.1%)
 III 23 (15.1%)
 IV 11 (7.2%)
Smoking
 Yes 120 (78.9%)
 No 23 (15.1%)
 No data 9 (5.9%)
EGFR mutation
 Mutant 22 (14.5%)
 Wild type 130 (85.5%)
KRAS mutation
 Mutant 34 (22.4%)
 Wild type 118 (77.6%)
P53 immunohistochemistry
 Positive 68 (44.7%)
 Negative 84 (55.3%)
EGFR, epidermal growth factor receptor; TNM, tumor, lymph node, and metastasis.
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Network from April 2005 to June 2009 were included in this 
study.27 Patient characteristics are shown in Table 1. Half the 
patients were women, there were more adenocarcinomas 
(61.8%), the majority were smokers (78.9%), and most had 
stage I disease (58.6%). The distribution of mutations and p53 
immunoreactivity was typical for North American NSCLC 
patients with 22 of 152 (14%) and 34 of 152 (22%) harboring 
EGFR and KRAS mutations, respectively.
PTEN Protein Expression
There were 54 and 35 cases with 1+ and 2+ stain-
ing (retained expression), respectively. Loss of PTEN 
expression (completely negative) was seen in 63 of 152 
cases (41.4%) (Table 2). PTEN loss was observed more 
frequently in men than in women (51% versus 33%, 
p = 0.032) and in SqCC than in AdC (59% versus 34%, 
p = 0.021). In patients who were lifetime nonsmokers, PTEN 
loss was seen in only 26%, but the difference compared with 
patients with a smoking history was not significant. A similar 
proportion of patients (27%) with EGFR mutations dem-
onstrated PTEN loss. There was no significant correlation 
between loss of PTEN expression and KRAS mutations or p53 
immunostaining status.
PTEN Copy Number Changes and 
Correlation with Protein Expression
FISH results were available for 124 of 152 cases, as some 
TMA cores failed to provide interpretable results because of 
loss of tumor-containing cores or poor hybridization. Seven 
cases (5.6%) demonstrated PTEN deletion, including hemizy-
gous loss in four cases, monosomy in two cases, and homozy-
gous loss in one case (Fig. 2). Unexpectedly, there were four 
cases with increased PTEN copy number: one with PTEN 
cluster formation, whereas the other three showed additional 
PTEN copies without PTEN cluster formation. All seven 
PTEN deleted cases were negative by PTEN IHC. However, 
49 cases without PTEN deletion demonstrated loss of PTEN 
protein expression. Six of the seven cases with PTEN deletions 
TABLE 2.  Correlation between PTEN Protein Expression by Immunohistochemistry and Gene Copy Changes by Fluorescence 
in situ Hybridization and Clinicopathological Characteristics
Clinicopathological
Characteristics
Protein Expression Gene Copy Deletion
Lost (%) Retained (%) p Present (%) Absent (%) p
PTEN 63 (41) 89 (59) 7 (5.6) 117 (94.4)
Age (yrs)
 Median (range) 66 (44–84) 68 (42–88) 0.966 67 (47–82) 67 (42–88) 0.94
Sex
 Female 25 (33) 52 (67) 0.032 4 (7) 55 (93) 0.71
 Male 38 (51) 37 (49) 3 (5) 62 (95)
Histology
 AdC 32 (34) 62 (66) 0.021 1 (1) 74 (99) 0.009
 SqCC 26 (59) 18 (41) 6 (16) 32 (84)
 Others 5 (36) 9 (64) 0 11 (100)
TNM stage
 I 33 (37) 56 (63) 0.29 3 (4) 69 (96) 0.66
 II 13 (45) 16 (55) 2 (8) 23 (92)
 III 13 (57) 10 (43) 2 (11) 17 (89)
 IV 4 (36) 7 (64) 0 8 (100)
Smoking
 Yes 56 (47) 64 (53) 0.107 6 (6) 93 (94) 1.0
 No 6 (26) 17 (74) 1 (6) 16 (94)
 No data 1 (11) 8 (89) 0 8 (100)
EGFR mutation
 Yes 6 (27) 16 (73) 0.167 1 (6) 16 (94) 1.0
 No 57 (44) 73 (56) 6 (6) 101 (94)
KRAS mutation
 Yes 14 (41) 20 (59) 1.00 0 25 (100) 0.34
 No 49 (42) 69 (58) 7 (7) 92 (93)
p53 IHC
 Positive Negative 28 (41)
35 (42)
40 (59)
49 (58)
1.00 4 (7)
3 (4)
53 (93)
64 (96)
0.70
AdC, adenocarcinoma; SqCC, squamous cell carcinoma; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; KRAS, ; TNM, tumor, lymph node, and metas-
tasis; PTEN, phosphatase and tensin homolog.
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FIGURE 2. Representative photo-
graphs (100× magnification) of dual-
color fluorescent in situ hybridization 
of non–small-cell lung tumors using 
probes for PTEN (green/FITC) and 
the centromere of chromosome 10 
centromeric probe (blue/aqua), with 
grayscale 6-diamidino-2-phenylindole 
nuclear stain: A, PTEN diploidy; (B), 
PTEN hemizygous loss as predomi-
nant pattern; (C), PTEN hemizygous 
loss with chromosome 10 monosomy 
as predominant pattern; (D), PTEN 
homozygous loss as predominant 
pattern. PTEN, phosphatase and 
tensin homolog.
FIGURE 3. Kaplan–Meier DFS curves based on PTEN immunohistochemistry status. A, All patients based on PTEN status show-
ing PTEN negative tumors were associated with poorer DFS compared with PTEN positive tumors. Adenocarcinomas (B) and 
(C) squamous cell carcinoma, according to PTEN status demonstrating significant differences in DFS based on histology. PTEN, 
phosphatase and tensin homolog; DFS, disease-free survival; CI, confidence interval; HR, hazard ratio.
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occurred in SqCC cases, accounting for 35.3% (6 of 17) of the 
PTEN-IHC–negative cases. In contrast, PTEN deletion was 
rare (1 of 75) in AdC cases.
Correlation between PTEN Protein Expression, 
PTEN Copy Number, and Survival
To determine the impact of PTEN status on clinical 
outcome, we assessed DFS for the 152 patients included in 
the IHC study. We initially correlated PTEN expression with 
survival according to the intensity of positive staining (1+, 
2+); however, we found no significant differences. Therefore 
we focused on comparisons between any intensity of staining 
(1+ and 2+) and complete absence of staining. The median 
follow-up time was 2.38 years (range, 0.07– 5.97 years). In 
univariate analysis, stage was a significant prognostic marker 
for DFS, but not age, sex, or histology. Patients with loss of 
PTEN expression had significantly worse outcome than those 
with retained PTEN expression (hazard ratio [HR] 1.76, 95% 
confidence interval [CI]: 1.02–3.01, log-rank p = 0.038; Fig. 
3A). In contrast, KRAS, EGFR, and p53 were not significantly 
prognostic (Table 3). The prognostic effect was, however, sig-
nificantly different when stratified by histology. In patients 
with adenocarcinoma, PTEN loss was associated with signifi-
cantly shorter DFS (HR 2.72, 95% CI: 1.41–5.26, log-rank p = 
0.002; Fig. 3B), whereas no differences were seen in squamous 
cell histology (Fig. 3C). In multivariate analysis adjusted for 
sex, age, histology, and stage (Table 3), loss of PTEN expres-
sion remained not only significant for shorter DFS in all his-
tologies (HR 1.78, 95% CI: 1.01–3.14, p = 0.048), but also 
for significantly shorter DFS in AdC only (HR 2.68, 95% CI: 
1.35–5.32, p = 0.005). Because of the very low number (n = 
7) of PTEN deleted cases, correlation with survival outcome 
was not performed.
DISCUSSION
In the present study, we found that 41% of NSCLCs 
tested had loss of PTEN protein expression by IHC. Although 
the lack of PTEN expression was significantly more fre-
quent in squamous cell carcinoma, it was only prognostic in 
patients with adenocarcinoma. Also, although PTEN deletions 
detected by FISH correlated with absent expression by IHC, 
these deletions were only detected in seven cases and most of 
these were squamous cell carcinomas.
The inactivation of PTEN frequently is found in a vari-
ety of tumors, including lung, endometrial, bladder, renal, and 
breast cancers.6 Absent PTEN expression has been reported to 
occur in 24% to 78% of NSCLC (Table 4). Among previously 
published studies,10,19,32–37 only two34,36 reported a significantly 
greater prevalence in SqCC (or non-AdC) than AdC (Table 
4), similar to what we have observed. In both of these studies 
and our own, a Cell Signaling antibody was used. However, 
only Scrima et al.36 identified the antibody as clone 138G6, the 
same clone used in this study. Antibody specificity has always 
been a poorly controlled factor in IHC studies. In the case 
of PTEN, Sangela et al.26 reported previously that the 138G6 
antibody was the most specific among the 11 antibodies that 
they evaluated. The greater frequency of PTEN loss of expres-
sion in men than in women could be related to the differential 
expression in SqCC versus AdC. In our study, there was no 
relationship between tumor stage and PTEN expression, in 
contrast to two other studies that suggested some correlation, 
yet reporting a contradictory relationship.10,19
In univariate analysis, patients with loss of PTEN 
expression had significantly worse outcome than those with 
retained PTEN expression (HR 1.76, 95% CI: 1.02–3.01, p 
= 0.038), and this association remained significant even after 
adjusting for other prognostic variables (HR 1.78, 95% CI: 
1.01–3.14, p = 0.048). Interestingly, when we investigated 
survival by histology, the poorer DFS associated with 
PTEN loss was only seen in AdCs. Table 4 also summarizes 
the literature correlating histology and survival to PTEN 
expression in NSCLC. Among seven studies that included 
survival outcome correlation with PTEN expression, 
six19,32–35,37 reported a significantly poorer prognosis for 
patients whose tumors showed absent or low PTEN expression.
There is, however, a lack of uniformity in the cutoff chosen 
for survival correlation, with many studies including low 
percentage or faint staining in their negative cases. Our results 
demonstrated that when using the Cell Signaling antibody 
clone 138G6, no difference in DFS was seen between faint 
PTEN (1+) and stronger PTEN staining intensity (2+). With 
this approach, the frequencies of negative cases are similar to 
ours, ranging from 24% to 65% of NSCLC.19,32,33,37 Other than 
TABLE 3. Correlation of Disease-Free Survival with PTEN 
Protein Expression and Other Clinical, Pathological, and 
Molecular Factors
Hazard 
Ratio
95% Confidence 
Interval Wald p
Univariate Analysis
 Sex (male vs. female) 1.04 0.61–1.79 0.88
 Age (≥65 vs. 65 yrs) 0.87 0.51–1.51 0.63
 Histology (AdC vs. others) 1.17 0.65–2.08 0.60
 Stage (III/IV vs. I/II) 2.42 1.37–4.25 0.0022
 PT EN immunohistochemistry  
(− vs. +)
1.76 1.02–3.01 0.041
 EG FR mutation (mutant vs. wild 
type)
0.99 0.47–2.11 0.98
 KR AS mutation  
(mutant vs. wild type)
1.57 0.87–2.83 0.13
 p53 immunohistochemistry  
(+ vs. −)
1.24 0.72–2.14 0.43
Multivariate analysis (Total)
 PTEN staining (− vs. +) 1.78 1.01–3.14 0.048
 Sex (male vs. female) 1.05 0.59–1.84 0.88
 Age 0.99 0.97–1.02 0.69
 Histology (AdC vs. others) 1.12 0.60–2.09 0.72
 Stage (III/IV vs. I/II) 2.32 1.29–4.20 0.005
Multivariate analysis (Adenocarcinoma only)
 PTEN staining (− vs. +) 2.68 1.35–5.32 0.005
 Sex (male vs. female) 0.74 0.37–1.47 0.39
 Stage (III/IV vs. I/II) 2.42 1.24–4.72 0.009
PTEN, phosphatase and tensin homolog; −, loss of expression; +, retained expres-
sion; AdC, Adenocarcinoma; EGFR, epidermal growth factor receptor; KRAS, 
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our own, one study33 reported low/absent PTEN expression 
as a significant independent prognostic marker in NSCLC 
patients. Our results further suggest that the differences in 
survival may be driven by the loss of PTEN in AdCs, as its 
prognostic significance was not apparent among the SqCC 
patients. A similar result was obtained by Wang et al.,32 whose 
study cohort included only AdC patients.
The role of PTEN in these tumors seems functionally 
important to oncogenesis as its loss results in the dysregula-
tion of Akt-dependent and Akt-independent pathways that are 
known to be critical for the progression of malignant can-
cers.38 The PI3K/AKT pathway has been implicated in tumor-
igenesis because of its role in cell survival and metabolism. 
The loss of PTEN expression may be induced by a variety 
of mechanisms, including homozygous deletion, nonsense 
mutation with loss of heterozygosity, and promoter meth-
ylation.37–39 Indeed, PTEN promoter methylation has been 
reported in a series of 132 NSCLC patients to be indepen-
dently associated with poorer prognosis when compared with 
unmethylated samples.38 It is recognized that mutation and 
homozygous deletion of PTEN in lung cancer are uncom-
mon events, whereas the frequency of hypermethylation of 
PTEN promoter is variable (0–35%).10,37–40 In our series, only 
seven cases were PTEN deleted by FISH and all seven cases 
showed loss of PTEN protein expression. Although PTEN 
copy number change may be a cause of PTEN inactivation in 
some patients, our study suggests that additional mechanisms 
for loss of PTEN protein expression in patients without copy 
number change are also important. Marsit et al.10 suggest that 
regulation of PTEN is not always at the genetic level but also 
may occur at the transcriptional or translational level, which 
may also explain the observed limited correlation between 
gene copy number and IHC.
Approximately 70% of tumors with EGFR-activating 
mutations respond to EGFR TKIs.41 However, some tumors 
demonstrate primary resistance to TKIs, and most will 
develop secondary resistance at some time point. The 
T790M EGFR mutation and amplification of MET are 
both recognized mechanisms of resistance.42,43 Recently, 
Yamamoto et al.23 reported that loss of PTEN expression 
contributes to gefitinib and erlotinib resistance in NSCLC, 
and Sos et al.22 reported a novel resistance mechanism in 
EGFR-mutant NSCLC involving PTEN loss. Furthermore, 
a recent retrospective study investigating the association of 
PTEN, PIK3CA, and EGFR copy number with responses to 
gefitinib, found that a combination of PTEN loss, PIK3CA 
gain, and EGFR copy number was associated with limited 
responses, especially in EGFR wild-type tumors.44 In our 
study, 22 of 152 cases harbored EGFR mutations, and six 
of these also demonstrated loss of PTEN by IHC. As these 
patients did not receive EGFR TKIs in the adjuvant setting, 
we do not have information on the sensitivity of these 
tumors to EGFR TKI therapy, although the abovementioned 
studies suggest that primary resistance might occur in these 
tumors.
Currently, there are several active early-phase clinical 
trials evaluating PI3K inhibitors either alone or in combina-
tion with chemotherapy, EGFR TKIs, or monoclonal antibod-
ies. Preliminary data suggest that such agents are effective T
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in tumors in which the PI3K-AKT pathway is activated, as 
occurs with mutations or gene amplification in the PIK3CA 
gene. PIK3CA mutations are uncommon but have been iden-
tified in 2% to 4% of primary NSCLC,45,46 predominantly in 
exons 9 and 20. As loss of PTEN results putatively in the con-
stitutive activation of the PI3K pathway, and this occurs more 
frequently than PIK3CA mutation/amplification, it is possible 
that more NSCLC and particularly AdCs may be susceptible to 
abrogation of the PI3K-AKT and that it may be advisable also 
to select patients by identifying the PTEN status rather than 
focusing purely on PIK3CA mutations or phosphorylated AKT.
In conclusion, we have demonstrated that although 
loss of PTEN protein expression occurs significantly more 
frequently in squamous cell histology, it exerts a signifi-
cant effect on DFS only in AdCs. This histological asso-
ciation may explain the discrepancies in PTEN results 
previously reported in NSCLC. Contrary to other studies, 
we did not find an association with p53 staining, nor with 
more advanced stage. The poorer DFS observed with PTEN 
loss was independent of EGFR and KRAS mutation status. 
Reasons for the observed prognostic differences associated 
with PTEN loss in AdC but not squamous cell carcinoma 
warrant further investigation. 
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